Investigator Clinical Trial Experience.

Investigator Network Experience

“RMP investigators consistently deliver accelerated enrollment and predictable study execution across multi-site programs.”

​

The investigators within the Research Management Partners (RMP) network represent a highly experienced group of physicians actively engaged in clinical research across multiple therapeutic areas. Serving as Principal Investigators and Sub-Investigators, they have collectively contributed to more than 150 industry-sponsored clinical trials spanning Phase I through Phase IV, including interventional, observational, and real-world evidence programs.

Operating within active clinical practices across Florida and Puerto Rico, our investigators provide direct access to large, diverse, and treatment-experienced patient populations. This embedded model enables accelerated enrollment, improved retention, and more accurate feasibility assessments—key drivers of successful study execution.

RMP investigators have extensive experience across psychiatry, pulmonology, gastroenterology, cardiology, endocrinology, rheumatology, infectious diseases, neurology, dermatology, and metabolic disorders. Their work has been conducted in collaboration with leading pharmaceutical and biotechnology sponsors including AbbVie, GSK, Pfizer, Novartis, Sanofi, Eli Lilly, UCB, Biogen, and other global research organizations.

All investigators operate within RMP’s centralized operational infrastructure, which integrates SOP-driven processes, regulatory oversight, study start-up coordination, and advanced CTMS/eSource technologies. This model ensures standardized execution, minimizes variability across sites, and consistently delivers high-quality data aligned with ICH-GCP, FDA, and IRB requirements.

By combining experienced investigators, strong patient access, and centralized operational support, RMP provides sponsors and CROs with a reliable, scalable, and high-performing research network designed to reduce operational risk and optimize study outcomes.

​

Representative Clinical Trial Experience

The following is a representative selection of clinical trials conducted by investigators within the RMP network across key therapeutic areas:

​

Psychiatry & CNS Disorders

• Phase III study in Major Depressive Disorder (MDD)

• Randomized study in Bipolar I Disorder (depressive episodes)

• Phase II study of a novel antipsychotic for schizophrenia

• Treatment-resistant depression clinical trial

• Phase II–III study in agitation associated with Alzheimer’s disease

• Multicenter study in early Alzheimer’s disease

• Phase IV maintenance study in bipolar disorder

• Adjunctive therapy study for negative symptoms of schizophrenia

• Relapse prevention study in major depressive disorder

Pulmonology & Respiratory Diseases

• Phase III study in Chronic Obstructive Pulmonary Disease (COPD)

• Study of roflumilast add-on therapy in COPD

• Randomized study in idiopathic pulmonary fibrosis (IPF)

• Multicenter study in asthma control and biologic therapy

• Pediatric asthma safety and efficacy trial

• Inhaled nitric oxide study in pulmonary hypertension associated with COPD

Gastroenterology & Hepatology

• Phase III study in Crohn’s disease (maintenance therapy)

• Phase III study in ulcerative colitis

• Phase III study in non-alcoholic steatohepatitis (NASH)

• Phase II study in irritable bowel syndrome with constipation (IBS-C)

• Hepatology study in liver fibrosis

• Multicenter study in Clostridium difficile vaccine prevention

Cardiology & Metabolic Diseases

• Randomized study of sacubitril-valsartan in heart failure

• Phase III study in heart failure with iron deficiency

• Cardiovascular safety study of celecoxib vs NSAIDs

• Hypercholesterolemia multicenter clinical trial

• Hypertension therapy conversion study

• Cardiovascular outcomes study in rheumatology populations

Endocrinology & Metabolic Disorders

• Randomized study in Type 2 Diabetes Mellitus

• Insulin therapy comparative study in Type 1 Diabetes

• Clinical trial in obesity and metabolic disorders

• Phase II study in chronic kidney disease-related anemia

• Study in hyperuricemia and gout

Neurology & Pain

• Phase II study in chronic migraine treatment

• Randomized trial in diabetic peripheral neuropathy pain

• Post-herpetic neuralgia treatment study

• Randomized study in chronic low back pain

• Acute migraine treatment study (microneedle delivery system)

Rheumatology & Immunology

• Phase III study in rheumatoid arthritis

• Study in psoriatic arthritis

• Study in plaque psoriasis

• Comparative study of biologic therapies

Infectious Diseases & Vaccines

• Phase III study in COVID-19 treatment

• CMV vaccine study

• Influenza vaccine immunogenicity study

• HIV treatment optimization study

Additional Research Programs

• Osteoporosis treatment study in postmenopausal women

• Dermatology study in tinea pedis

• Chronic urticaria and dermatology immunology trials

• Pharmacogenomic registry studies

• Long-term safety extension studies

Biospecimen & Observational Research

• Biospecimen collection supporting genomic drug development

• Longitudinal registry evaluating real-world patient outcomes

• Observational studies assessing long-term safety of approved therapies

Closing Statement 

​

Through this breadth of experience, RMP offers sponsors and CROs access to investigators who are not only clinically experienced but operationally supported within a fully integrated research infrastructure—enabling faster activation timelines, reliable enrollment, and consistent, high-quality study execution across a scalable network of sites.